Skip to main content
Clinical Trials/NCT04485741
NCT04485741
Completed
Not Applicable

Clinical Utility of Strados System in Periodically Recording Auscultation to Provide Replay Capability and Telemedicine Monitoring of Inpatients After Initial Clinical Assessment.

Strados Labs, Inc.1 site in 1 country30 target enrollmentSeptember 23, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Copd
Sponsor
Strados Labs, Inc.
Enrollment
30
Locations
1
Primary Endpoint
Clinical utility as assessed by the PI
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Listening to breath sounds with the stethoscope/auscultation is used by pulmonary physicians in conjunction with pulmonary function, signs and symptoms, oxygen saturation and diagnostic testing to admit, follow and discharge patients from hospital. Of these, only auscultation routinely ceases upon discharge from Hospital. Healthcare utilization statistics have shown that for more than a decade, readmission after discharge for an exacerbation of COPD or severe asthma (or chronic heart failure) remains a major problem. The Strados System has been designed to extend the range of lung sound recording both geographically and temporally to improve the standard of care when access to continuous monitoring has been replaced by periodic or no monitoring. The primary purpose of this study is to assess the clinical utility of the Strados System in enabling periodic recording and reviewing of breath sounds in patients with chronic respiratory diseases, either in the ICU, or in less continuously monitored settings, including after inpatient discharge.

Registry
clinicaltrials.gov
Start Date
September 23, 2020
End Date
December 31, 2021
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Potential study participants will be recruited from within the Einstein Center of Excellence. Individuals who meet all of the following criteria are eligible for enrollment as study participants:
  • Males and females between the ages of 18-80:
  • With documented physician-diagnosed COPD (chronic bronchitis dominant) or severe asthma, as defined either by the American Thoracic Society or the World Health Organization who are admitted for exacerbation, including those with active or suspected SARS-COV-2 infection
  • Who are admitted with respiratory distress symptoms associated with SARS-COV-2 infection
  • Able to provide informed consent
  • Able to follow study procedures
  • Clinician assessment of the patient's current SARS-COV-2 status: negative or unlikely to be infected, RTPCR positive, or untested by clinically suspected
  • Accessible by telephone upon discharge

Exclusion Criteria

  • Subjects who meet ANY of the following criteria are not eligible for enrollment:
  • Inability or unwillingness of the participant to give written informed consent
  • History of adverse reaction or allergy to Tegaderm
  • Unwillingness or inability to comply with study procedures
  • Scheduled for thoracic procedure
  • Inaccessible by telephone post-discharge

Outcomes

Primary Outcomes

Clinical utility as assessed by the PI

Time Frame: Periodic recording over 12 to 24 hours

To assess the clinical utility of Strados Systems in enabling periodic recording and reviewing of lung breath sounds of inpatients with chronic respiratory diseases in ICU , and less continuously monitored settings.

Secondary Outcomes

  • Correlation of RESP data with other measures of patient status.(Periodic recording over 12 to 24 hours)
  • Clinical utility as assessed by other clinicians(Periodic recording over 12 to 24 hours)

Study Sites (1)

Loading locations...

Similar Trials